home / stock / angn / angn news


ANGN News and Press, Angion Biomedica Corp. From 09/24/21

Stock Information

Company Name: Angion Biomedica Corp.
Stock Symbol: ANGN
Market: NASDAQ

Menu

ANGN ANGN Quote ANGN Short ANGN News ANGN Articles ANGN Message Board
Get ANGN Alerts

News, Short Squeeze, Breakout and More Instantly...

ANGN - Angion Biomedica (ANGN) Investor Presentation - Slideshow

The following slide deck was published by Angion Biomedica Corp. in conjunction with this event. For further details see: Angion Biomedica (ANGN) Investor Presentation - Slideshow

ANGN - Catalyst watch for next week: FedEx and Nike report, FOMC watch, IPO blitz

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. ...

ANGN - Angion Hosting Research & Development Day on ANG-3070 for the Treatment of Lung and Kidney Fibrosis

UNIONDALE, N.Y., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, announced...

ANGN - Angion to Participate in Upcoming September Investment Conferences

UNIONDALE, N.Y., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today anno...

ANGN - Angion Biomedica reports Q2 results

Angion Biomedica (NASDAQ:ANGN): Q2 GAAP EPS of -$0.58. As of June 30, 2021, Angion had cash and cash equivalents totaling $117.3 million.  Press Release For further details see: Angion Biomedica reports Q2 results

ANGN - Angion Provides Corporate Update and Reports Second Quarter 2021 Financial Results

-- Topline data in ANG-3777 Phase 3 study now expected to be announced in early Q4 rather than at year end -- Phase 1 data demonstrated ANG-3070 was well-tolerated across dose cohorts, achieving drug exposures in humans exceeding exposures in which activity was demonstrated in a...

ANGN - Angion Reports Positive Results from Phase 1 Healthy Volunteer Study for ANG-3070 and FDA Authorization to Initiate Phase 2 Trial in 2021

ANG-3070 was well-tolerated across dose cohorts, achieving drug exposures in humans exceeding exposures in which activity was demonstrated in animal models of proteinuric kidney diseases Pharmacokinetic data potentially supportive of once-daily dosing An international Ph...

ANGN - Wall Street Breakfast: The Week Ahead (Podcast)

You can read full article here. For further details see: Wall Street Breakfast: The Week Ahead (Podcast)

ANGN - Wall Street Breakfast: The Week Ahead

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead Another huge week of earnings is on tap with more than a quarter of S&P 500 companies due to report, including compe...

ANGN - Seeking Alpha Catalyst Watch

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Previous 10 Next 10